It’s only fair to share… BPI-7711, Rezivertinib 1835667-12-3 C27H30N6O3, 486.576 N-[2-[2-(dimethylamino)ethoxy]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide Beta Pharma in collaboration Chinese licensee CSPC Pharmaceuticals Group , is developing BPI-7711 In June 2021, this drug was reported to be in phase 3 clinical development. OriginatorBeta Pharma ClassAmides; Amines; Antineoplastics; Indoles; Phenyl ethers; Pyrimidines; Small molecules Mechanism of ActionEpidermal growth factor receptor antagonists …